Follow
José Ángel Hernandez
José Ángel Hernandez
Universidad Complutense. Hospital Infanta Leonor
Verified email at salud.madrid.org
Title
Cited by
Cited by
Year
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008
5132008
Química da madeira
U Klock, GIB Muñiz, JA HERNANDEZ, AS Andrade
Fupef, Curitiba, 2005
3582005
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases
R García‐Sanz, S Montoto, A Torrequebrada, AG De Coca, J Petit, ...
British journal of haematology 115 (3), 575-582, 2001
2982001
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
2972020
Global retinoblastoma presentation and analysis by national income level
ID Fabian, E Abdallah, SU Abdullahi, RA Abdulqader, SA Boubacar, ...
JAMA oncology 6 (5), 685-695, 2020
2652020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ...
Leukemia 34 (9), 2354-2363, 2020
2602020
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
J García-Suárez, J de la Cruz, Á Cedillo, P Llamas, R Duarte, ...
Journal of hematology & oncology 13, 1-12, 2020
2262020
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
SE Kasner, B Swaminathan, P Lavados, M Sharma, K Muir, R Veltkamp, ...
The Lancet Neurology 17 (12), 1053-1060, 2018
1832018
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
TJ González‐López, C Pascual, MT Álvarez‐Román, ...
American journal of hematology 90 (3), E40-E43, 2015
1732015
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
TJ González‐López, C Pascual, MT Álvarez‐Román, ...
American journal of hematology 90 (3), E40-E43, 2015
1702015
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
S Rule, M Dreyling, A Goy, G Hess, R Auer, B Kahl, JÁ Hernández-Rivas, ...
Haematologica 104 (5), e211, 2019
1512019
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
L Lopez-Corral, ME Sarasquete, S Beà, R García-Sanz, MV Mateos, ...
Leukemia 26 (12), 2521-2529, 2012
1272012
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis
F Cavazzini, JA Hernandez, A Gozzetti, A Russo Rossi, C De Angeli, ...
British journal of haematology 142 (4), 529-537, 2008
1252008
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia
JÁ Hernández, AE Rodríguez, M González, R Benito, C Fontanillo, ...
haematologica 94 (3), 364, 2009
1082009
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
ML Wang, W Jurczak, M Jerkeman, J Trotman, PL Zinzani, D Belada, ...
New England Journal of Medicine 386 (26), 2482-2494, 2022
1032022
Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and …
B Paiva, MC Montes, R García-Sanz, EM Ocio, J Alonso, N de Las Heras, ...
Leukemia 28 (1), 166-173, 2014
992014
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
B Paiva, NC Gutierrez, X Chen, MB Vidriales, MÁ Montalbán, L Rosinol, ...
Leukemia 26 (8), 1862-1869, 2012
932012
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
B Paiva, MB Vidriales, G Mateo, JJ Perez, MA Montalbán, A Sureda, ...
Blood, The Journal of the American Society of Hematology 114 (20), 4369-4372, 2009
912009
Detection of tumor cells in the peripheral blood of nonleukemic patients with B-cell lymphoma: analysis of “clonal excess”
FS Ligler, RG Smith, JR Kettman, JA Hernandez, JB Himes, ES Vitetta, ...
Blood 55 (5), 792-801, 1980
881980
Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study …
JM Ribera, O García, C Grande, J Esteve, A Oriol, J Bergua, ...
Cancer 119 (9), 1660-1668, 2013
862013
The system can't perform the operation now. Try again later.
Articles 1–20